•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

Through this new vehicle, Catalio seeks to provide the next generation of breakthrough biomedical technology companies with bespoke debt and structured equity solutions that are tailored to fit their unique financing needs. The Fund will equip founders and companies with the flexibility and runway required to achieve their next critical milestones - at a lower cost of capital than traditional equity - while generating strong risk-adjusted returns for investors through a combination of contractual cashflows, current income and down-side protected forms of equity participation.

"In this challenging market, we are seeing significant demand from biotech companies for structured capital financing solutions to reach the next step in their evolution," said George Petrocheilos and Dr. Jacob Vogelstein, Co-Founders and Managing Partners of Catalio. "We believe that this strategy provides exciting biotech companies the necessary capital and flexibility to scale their platforms."

Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies. The Fund is the second investment vehicle that Catalio has raised in 2022, following the close of Catalio Nexus Fund III, the firm's third flagship private equity fund, earlier this year.

About Catalio Capital Management
Catalio Capital Management, LP, is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio's Partnership includes over 39 world-renowned scientists with extensive academic and scientific achievements who have each started several successful companies based on their research. Catalio has offices in New York, Baltimore, and London.

Press release
Bg

Article source - Opalesque is not responsible for the content of external internet sites